box10.gif (1299 bytes)







Diagnostic imaging

ART secures two orders for molecular imaging system

MONTREAL – ART Advanced Research Technologies Inc., a developer of optical molecular imaging products for the healthcare and pharmaceutical industries, announced that it has received two orders for the recently released preclinical optical molecular imager, Optix MX2. The units are expected to be shipped before the end of the year.

This represents the first Optix units sold by ART under its new commercial strategy. The company said it preferred not to disclose the names of the buyers of the new equipment.

“These orders of the Optix MX2 system demonstrate that we are on track to achieve revenue growth with our new commercialization strategy under the leadership of Dino DiCamillo, our new global sales and marketing executive for preclinical imaging,” said Sebastien Gignac, President and CEO of ART.

“ART is building sales momentum with the new team in place and leveraging internal expertise in optical imaging to offer multiple solutions to Optix users,” concluded Dino DiCamillo, ART’s Vice President, Global Sales & Marketing for Preclinical Imaging.

About the Optix system

Based on time-domain technology, which allows measurement of the light’s time of arrival, the Optix in vivo optical molecular imaging device is the most sensitive optical imager commercially available on the precinical market, allowing for detection of lower concentrations of signals deeper inside the body, the company says.

Unique to the Optix system is the ability to recover fluorescence lifetime, which can be used to separate and quantify probe distributions depending on their respective biochemical environment. Also part of the Optix product offering is a new CT fusion software package allowing researchers to export the scan obtained using Optix in DICOM format, and fuse it with Micro CT for a full 3D anatomical reference.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed directly by ART in North America and Europe and is used by industry and academic leaders worldwide.

The SoftScan optical breast imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing the SoftScan optical medical imaging device via a global strategic alliance with GE Healthcare, a world leader in mammography and imaging.

Finally, the Fenestra line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. The distribution of the Fenestra line of imaging contrast agents is made through GE Healthcare Bio-Science KK in Japan and is sold directly by the Company in the rest of the world. ART’s shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit